Clinical research organization Clinipace Worldwide has acquired Regulus Pharmaceutical Consulting in a move to expand its regulatory and development capabilities.
Financial terms of Morrisville, North Carolina-based Clinipace’s acquisition of Regulus were not disclosed. But Clinipace said it will keep the Regulus team intact and working from its current location in Boulder, Colorado.
Regulus now becomes the consultancy division within Clinipace covering regulatory affairs, strategic development and quality assurance. Regulus President Brenda Fielding will stay on with the company as executive vice president of regulatory affairs for Clinipace.
Clinipace was founded by CEO Jeff Williams in 2003 as a “digital CRO” offering clinical trial services through its proprietary software. Beside organic growth, the company has also been growing through acquisition. In 2009, the company acquired Kansas-based CRO Worldwide Clinical Research in a deal that gave the North Carolina company new expertise in oncology as well as a presence in South America. With the Regulus acquisition, Clinipace beefs up its regulatory capabilities to offer a wider array of services to pharmaceutical companies.
Clinipace’s last round of financing was a $2.6 million series B round in 2007 led by Hatteras Venture Partners. Clinipace says it is profitable and projects that its 2011 sales will top $20 million.
